Big Pharma Firms Partner Early At RESI Boston: Panel Announcement

9 Aug

By Lucy Parkinson, VP of Investor Research, LSN

In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines. This RESI Boston panel will feature five speakers and a moderator from various big pharma companies discussing topics such as:


  •     How big pharma sources assets
  •     The evaluation and investment process
  •     Key factors of interest
  •     How early-stage big pharma is willing to look

At RESI Boston on September 6th, we welcome five speakers from major pharma firms who will explain how they evaluate early stage companies for potential licensing and partnership relationships.  The panelists are:

  • Alex Rabiee, Director, Business Development, Amgen
  • Lizabeth Leveille, Head, Boston Innovation Hub, Merck
  • Imran Nasrullah, Director, BD&L, Strategic Partnering, Boehringer Ingelheim
  • Niels Emmerich, Senior Director, Global Head Search & Evaluation Oncology, AbbVie
  • Tim Luker, VP External Innovation, Eli Lilly

These panelists will shed light on the process that big pharma goes through when sourcing early-stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: